Home › Companies › Spyre Therapeutics, Inc. › 2025-2026

Spyre Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Spyre Therapeutics, Inc.’s Form 8-K, filed May 29, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.

6Reported items
219Asset managers
1,672Fund votes
May 27, 2026Meeting date

Results at a glance

Meeting of May 27, 2026: 6 items on Spyre Therapeutics, Inc.’s Form 8-K, filed May 29, 2026: 3 approved · 3 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2024-2025 2025-2026

Explore Spyre Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Spyre Therapeutics, Inc.

These tallies are Spyre Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Spyre Therapeutics, Inc. — official shareholder meeting results, meeting held May 27, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Mark McKenna	65,608,709	--	--	1,329,489	1,500,346	98%	Not verified	—
Elect Director: Cameron Turtle, D. Phil.	66,176,245	--	--	761,953	1,500,346	99%	Not verified	—
Elect Director: Laurie Stelzer	56,954,664	--	--	9,983,534	1,500,346	85%	Not verified	—
2. On a non-binding, advisory basis, the compensation of the Company's named executive officers	62,075,459	4,760,373	102,366	--	1,500,346	93%	Approved	—
3. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026	68,430,566	670	7,308	--	0	99.9%	Approved	—
4. The Company's AR ESPP	66,885,864	45,542	6,792	--	1,500,346	99.9%	Approved	—

Source: Spyre Therapeutics, Inc., Form 8-K, filed with the SEC on May 29, 2026 — read the filing on EDGAR.

How asset managers voted at the Spyre Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 219 asset managers that disclosed a Spyre Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Spyre Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Cameron Turtle, D. Phil.

Outcome not verified Fund totals may overlapDIRECTOR ELECTIONSReported outcome: Not verified

Combines 7 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 66,176,245WITHHELD: 761,953

Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Cameron Turtle, D.Phil.

Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Cameron Turtle, D. Phil.”): 66,176,245 for, 761,953 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 66 asset managers voting on “Election of Class I Directors for terms expiring in 2029: Cameron Turtle, D.Phil.” at Spyre Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Fidelity	9,366,962	0	0	For
Vanguard	3,604,700	1	0	For
Capital Group	2,412,693	0	0	For
BlackRock	2,015,808	0	0	For
T. Rowe Price	1,262,166	0	0	For
State Street	658,596	0	0	For
Charles Schwab	561,767	0	0	For
JPMorgan	524,155	0	0	For
DRIEHAUS MUTUAL FUNDS	414,759	0	0	For
Victory Capital	326,801	0	0	For
FRANKLIN STRATEGIC SERIES	323,584	0	0	For
RBB FUND, INC.	65,274	0	252,945	Mixed
First Trust	178,135	0	0	For
Hartford	168,893	0	0	For
Principal	4,299	0	155,168	Withhold
Equitable	157,755	0	0	For
TIAA	144,924	0	0	For
TRUST FOR PROFESSIONAL MANAGERS	82,062	0	0	For
Brighthouse	77,601	0	3,558	For
Northwestern Mutual	74,126	0	0	For
Jackson National	67,170	0	0	For
John Hancock	60,959	0	0	For
Lincoln Financial	52,674	0	0	For
Columbia Threadneedle	49,311	0	0	For
AIG/SunAmerica	42,071	0	0	For

Fund voting reports, all 66 managers: 23,088,662 for, 411,671 withheld, 1 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 1 asset manager voting on “Election of Class I Directors for terms expiring in 2029: Cameron Turtle, D.Phil.” at Spyre Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Remedium Capital Partners, LLC	1,456,231	0	0	0	For

Institutional-manager reports, all 1 managers: 1,456,231 for.

2. Elect Director: Laurie Stelzer

Outcome not verified Fund totals may overlapDIRECTOR ELECTIONSReported outcome: Not verified

Combines 7 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD

FOR: 56,954,664WITHHELD: 9,983,534

Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Laurie Stelzer

Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Laurie Stelzer”): 56,954,664 for, 9,983,534 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports: 66 asset managers voting on “Election of Class I Directors for terms expiring in 2029: Laurie Stelzer” at Spyre Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Fidelity	9,366,962	0	0	For
Vanguard	3,602,011	15	2,674	For
Capital Group	2,412,693	0	0	For
BlackRock	2,015,808	0	0	For
T. Rowe Price	1,262,166	0	0	For
State Street	1,384	0	657,212	Withhold
Charles Schwab	561,767	0	0	For
JPMorgan	524,155	0	0	For
DRIEHAUS MUTUAL FUNDS	0	0	414,759	Withhold
Victory Capital	0	0	326,801	Withhold
FRANKLIN STRATEGIC SERIES	323,584	0	0	For
RBB FUND, INC.	0	0	318,219	Withhold
First Trust	0	0	178,135	Withhold
Hartford	168,893	0	0	For
Principal	0	0	159,467	Withhold
Equitable	112,825	0	44,930	Mixed
TIAA	144,924	0	0	For
TRUST FOR PROFESSIONAL MANAGERS	0	82,062	0	Abstain
Brighthouse	53,625	0	27,534	Mixed
Northwestern Mutual	74,126	0	0	For
Jackson National	0	67,170	0	Abstain
John Hancock	42,692	18,267	0	Mixed
Lincoln Financial	7,274	0	45,400	Mixed
Columbia Threadneedle	0	0	49,311	Withhold
AIG/SunAmerica	0	0	42,071	Withhold

Fund voting reports, all 66 managers: 20,823,005 for, 2,495,688 withheld, 181,641 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 1 asset manager voting on “Election of Class I Directors for terms expiring in 2029: Laurie Stelzer” at Spyre Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Remedium Capital Partners, LLC	1,456,231	0	0	0	For

Institutional-manager reports, all 1 managers: 1,456,231 for.

3. Elect Director: Mark McKenna

Outcome not verified Fund totals may overlapDIRECTOR ELECTIONSReported outcome: Not verified

Combines 8 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 65,608,709WITHHELD: 1,329,489

Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Mark McKenna

Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Mark McKenna”): 65,608,709 for, 1,329,489 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports: 66 asset managers voting on “Election of Class I Directors for terms expiring in 2029: Mark McKenna” at Spyre Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Fidelity	9,366,962	0	0	For
Vanguard	3,604,699	2	0	For
Capital Group	2,412,693	0	0	For
BlackRock	2,015,808	0	0	For
T. Rowe Price	1,262,166	0	0	For
State Street	658,406	0	190	For
Charles Schwab	561,767	0	0	For
JPMorgan	524,155	0	0	For
DRIEHAUS MUTUAL FUNDS	414,759	0	0	For
Victory Capital	326,801	0	0	For
FRANKLIN STRATEGIC SERIES	323,584	0	0	For
RBB FUND, INC.	65,274	0	252,945	Mixed
First Trust	178,135	0	0	For
Hartford	168,893	0	0	For
Principal	4,299	0	155,168	Withhold
Equitable	112,825	0	44,930	Mixed
TIAA	144,924	0	0	For
TRUST FOR PROFESSIONAL MANAGERS	82,062	0	0	For
Brighthouse	77,601	0	3,558	For
Northwestern Mutual	74,126	0	0	For
Jackson National	67,170	0	0	For
John Hancock	60,959	0	0	For
Lincoln Financial	52,674	0	0	For
Columbia Threadneedle	49,311	0	0	For
AIG/SunAmerica	42,071	0	0	For

Fund voting reports, all 66 managers: 23,043,540 for, 456,791 withheld, 2 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 1 asset manager voting on “Election of Class I Directors for terms expiring in 2029: Mark McKenna” at Spyre Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Remedium Capital Partners, LLC	1,456,231	0	0	0	For

Institutional-manager reports, all 1 managers: 1,456,231 for.

4. TO APPROVE THE COMPANY'S AMENDED AND RESTATED 2016 EMPLOYEE STOCK PURCHASE PLAN.

No official matchCOMPENSATION

99.9% of fund votes cast · no official result

FOR

Details: votes by 67 asset managers

The 67 asset managers below reported 23,490,367 for, 10,401 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 23,490,367AGAINST: 10,401

Largest asset managers voting on “TO APPROVE THE COMPANY'S AMENDED AND RESTATED 2016 EMPLOYEE STOCK PURCHASE PLAN.” at Spyre Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	9,366,962	0	For
Vanguard	3,599,112	5,589	For
Capital Group	2,412,693	0	For
BlackRock	2,015,808	0	For
T. Rowe Price	1,262,166	0	For
State Street	657,711	885	For
Charles Schwab	561,767	0	For
JPMorgan	524,155	0	For
DRIEHAUS MUTUAL FUNDS	414,759	0	For
Victory Capital	326,801	0	For
FRANKLIN STRATEGIC SERIES	323,584	0	For
RBB FUND, INC.	318,219	0	For
First Trust	178,135	0	For
Hartford	168,893	0	For
Principal	159,467	0	For
Equitable	157,755	0	For
TIAA	144,924	0	For
TRUST FOR PROFESSIONAL MANAGERS	82,062	0	For
Brighthouse	77,601	3,558	For
Northwestern Mutual	74,126	0	For
Jackson National	67,170	0	For
John Hancock	60,959	0	For
Lincoln Financial	52,674	0	For
Columbia Threadneedle	49,311	0	For
AIG/SunAmerica	42,071	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

5. 2. On a non-binding, advisory basis, the compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%

FOR: 62,075,459AGAINST: 4,760,373

Details: description as filed, official tally, votes by 219 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Spyre Therapeutics, Inc.’s own tally for this item (“2. On a non-binding, advisory basis, the compensation of the Company's named executive officers”): 62,075,459 for, 4,760,373 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports: 66 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Spyre Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	9,366,962	0	0	For
Vanguard	3,602,018	2,682	0	For
Capital Group	0	2,412,693	0	Against
BlackRock	2,015,808	0	0	For
T. Rowe Price	1,262,166	0	0	For
State Street	658,327	269	0	For
Charles Schwab	0	561,767	0	Against
JPMorgan	524,155	0	0	For
DRIEHAUS MUTUAL FUNDS	414,759	0	0	For
Victory Capital	326,801	0	0	For
FRANKLIN STRATEGIC SERIES	323,584	0	0	For
RBB FUND, INC.	318,219	0	0	For
First Trust	178,135	0	0	For
Hartford	168,893	0	0	For
Principal	159,467	0	0	For
Equitable	157,755	0	0	For
TIAA	144,924	0	0	For
TRUST FOR PROFESSIONAL MANAGERS	82,062	0	0	For
Brighthouse	77,601	0	3,558	For
Northwestern Mutual	74,126	0	0	For
Jackson National	67,170	0	0	For
John Hancock	60,959	0	0	For
Lincoln Financial	52,674	0	0	For
Columbia Threadneedle	49,311	0	0	For
AIG/SunAmerica	42,071	0	0	For

Fund voting reports, all 66 managers: 20,419,744 for, 3,077,031 against, 3,558 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 170 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Spyre Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	11,224,215	0	For
RTW INVESTMENTS, LP	4,191,364	0	For
Fairmount Funds Management LLC	4,018,101	0	For
Venrock Adviser, LLC	3,685,448	0	For
PERCEPTIVE ADVISORS LLC	2,587,491	0	For
Capital Group	0	2,412,693	Against
Commodore Capital LP	1,806,463	0	For
State Street	1,702,478	10,432	For
T. Rowe Price	1,700,504	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	1,666,378	0	For
RA CAPITAL MANAGEMENT, L.P.	1,621,620	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,593,687	0	For
Polar Capital Holdings Plc	1,499,662	0	For
Remedium Capital Partners, LLC	1,456,231	0	For
Wellington	1,070,333	0	For
BRAIDWELL LP	932,823	0	For
FRANKLIN ADVISERS INC	879,501	0	For
Siren, L.L.C.	818,598	0	For
BlackRock	660,128	7,794	For
Caligan Partners LP	662,832	0	For
Affinity Asset Advisors, LLC	591,286	0	For
Charles Schwab	0	562,659	Against
Vanguard	543,011	0	For
Paradigm Biocapital Advisors LP	518,054	0	For
Candriam S.C.A.	0	456,582	Against

Institutional-manager reports, all 170 managers: 49,049,364 for, 4,290,166 against, 5,692 abstained, 696 not voted. Showing the 25 largest; see all in the interactive database.

6. 3. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending…

Official result Fund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%

FOR: 68,430,566AGAINST: 670

Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.

Spyre Therapeutics, Inc.’s own tally for this item (“3. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 68,430,566 for, 670 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports: 66 asset managers voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE Y” at Spyre Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	9,366,962	0	For
Vanguard	3,604,701	0	For
Capital Group	2,412,693	0	For
BlackRock	2,015,808	0	For
T. Rowe Price	1,262,166	0	For
State Street	658,596	0	For
Charles Schwab	561,767	0	For
JPMorgan	524,155	0	For
DRIEHAUS MUTUAL FUNDS	414,759	0	For
Victory Capital	326,801	0	For
FRANKLIN STRATEGIC SERIES	323,584	0	For
RBB FUND, INC.	318,219	0	For
First Trust	178,135	0	For
Hartford	168,893	0	For
Principal	159,467	0	For
Equitable	157,755	0	For
TIAA	144,924	0	For
TRUST FOR PROFESSIONAL MANAGERS	82,062	0	For
Brighthouse	77,601	3,558	For
Northwestern Mutual	74,126	0	For
Jackson National	67,170	0	For
John Hancock	60,959	0	For
Lincoln Financial	52,674	0	For
Columbia Threadneedle	49,311	0	For
AIG/SunAmerica	42,071	0	For

Fund voting reports, all 66 managers: 23,496,776 for, 3,558 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 1 asset manager voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE Y” at Spyre Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Remedium Capital Partners, LLC	1,456,231	0	0	0	For

Institutional-manager reports, all 1 managers: 1,456,231 for.

Largest Spyre Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 78,839,858 shares outstanding at the time of that meeting.

Fund voting reports: top Spyre Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	11.88%
2	Vanguard	4.57%
3	Capital Group	3.06%
4	BlackRock	2.56%
5	T. Rowe Price	1.60%
6	State Street	0.84%
7	Charles Schwab	0.71%
8	JPMorgan	0.66%
9	DRIEHAUS MUTUAL FUNDS	0.53%
10	Victory Capital	0.41%

Institutional-manager reports: top Spyre Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	14.24%
2	RTW INVESTMENTS, LP	5.32%
3	Fairmount Funds Management LLC	5.10%
4	Venrock Adviser, LLC	4.67%
5	PERCEPTIVE ADVISORS LLC	3.28%
6	Capital Group	3.06%
7	Commodore Capital LP	2.29%
8	State Street	2.17%
9	T. Rowe Price	2.16%
10	DRIEHAUS CAPITAL MANAGEMENT LLC	2.11%

Reported Spyre Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Spyre Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	14.94%	13F
Peter Harwin	11.44%	13D
Tomas Kiselak	11.15%	DEF14A
Fairmount Healthcare Fund II L.P.	10.49%	DEF14A
FMR LLC	9.67%	DEF14A
BlackRock	7.00%	13F
Perceptive Advisors LLC	5.48%	13G
RTW Investments, LP	5.39%	13G
Vanguard Group	5.12%	13F
State Street	3.31%	13F

Percentages above are of 78,839,858 shares outstanding, as reported by Spyre Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Spyre Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Spyre Therapeutics, Inc.'s shareholder meeting held May 27, 2026, in the 2025-2026 proxy season, 219 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,672 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — Spyre Therapeutics, Inc.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Spyre Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2026.

Spyre Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.